Journal article
Correlation of chemotherapy delivery and survival outcomes of follicular lymphoma in the immunchemotherapy era
Journal of clinical oncology, Vol.31(15_suppl), pp.8563-8563
05/20/2013
DOI: 10.1200/jco.2013.31.15_suppl.8563
Abstract
8563 Background: Optimal initial treatment of follicular lymphoma (FL) is unknown. Rituximab as monotherapy (R) or as a component of immunochemotherapy (R+Chemo) is established as effective and it is now reasonable to re-examine the role of chemotherapy dosing. We explored clinical features, systemic treatment and chemotherapy delivery with comparative effectiveness of delivered dose intensity (DDI) on outcomes. Methods: We reviewed the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource database along with medical records on newly diagnosed grade I-IIIa FL who received systemic therapy from 2002 to 2009. Presenting clinicopathologic factors, outcomes and systemic therapy details including doses of chemotherapy were collected. The event-free (EFS) and overall survival (OS) effects of systemic therapy and chemotherapy DDI were analyzed with multivariate Cox regression. Confounding effects of FLIPI, grade, stage, and age were considered in the analysis. Results: From 2002 to 2009, 631 newly diagnosed FL were enrolled. Median follow up duration was 52.7 months. We identified 322 grade I-IIIa FL treated with systemic therapy including 93 R and 229 R+Chemo. Age and stage were similarly distributed between the R and R+Chemo groups; however, patients in the R group had lower grade (p<0.01) and FLIPI (p=0.03). Multivariate analysis showed no significant differences in EFS (HR=1.24, p=0.28) or OS (HR=0.55, p=0.13) for R compared to R+Chemo. Among R-CVP or R-CHOP treated FL, DDI data were collected for 73 doxorubicin (dox) and 137 cyclophosphamide (cyc) patients. Eighty-five percent of patients received 90% or more pre-planned DDI. After controlling for confounding factors, higher cycDDI was associated with improved EFS (HR 0.55, P=0.04) and OS (HR 0.74, P=0.03). No significant OS or EFS effects of doxDDI were observed. Conclusions: Addition of chemotherapy to rituximab was not associated with a detectable difference in survival outcomes in grade I-IIIa FL at a median follow-up of 52.7 months. Among R+Chemo treated FL, chemotherapy was delivered completely in most patients and more completed delivery of cyclophosphamide was associated with improved EFS and OS.
Details
- Title: Subtitle
- Correlation of chemotherapy delivery and survival outcomes of follicular lymphoma in the immunchemotherapy era
- Creators
- Kitsada Wudhikarn - University of IowaAnna M Button - University of IowaBrian J. Smith - University of IowaThomas Matthew Habermann - Mayo ClinicCarrie A. Thompson - Mayo ClinicJames Robert Cerhan - Mayo ClinicBrian K. Link - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Journal of clinical oncology, Vol.31(15_suppl), pp.8563-8563
- DOI
- 10.1200/jco.2013.31.15_suppl.8563
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2013
- Academic Unit
- Biostatistics; Holden Comprehensive Cancer Center; Epidemiology; Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984227043802771
Metrics
2 Record Views